Skip to main content
SpringerLink
Log in

HER2-Targeted Therapy

  • Chapter
Management of Breast Diseases

  • 1905 Accesses

Abstract

Up to 25% of women with breast cancer have tumors, which are human epidermal growth factor receptor-2 (HER2) positive, associated with an aggressive phenotype, higher recurrence rate and reduced survival [1, 2]. In these patients with poorer prognosis, combination chemotherapy (±endocrine therapy), up until recently, was the only treatment modality available.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:177–82

    Article  CAS  PubMed  Google Scholar 

  2. Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:707–12

    Article  CAS  PubMed  Google Scholar 

  3. Yarden Y (2001) The EGFR family and its ligands in human cancer: signaling mechanisms and therapeutic opportunities. Eur J Cancer. 37(Suppl 4):S3–8

    Article  Google Scholar 

  4. Schechter AL, Stern DF, Vaidyanathan L et al (1984) The neu oncogene: an erb-B-related gene encoding a 185,000-M, tumor antigen. Nature. 312:513–6

    Article  CAS  PubMed  Google Scholar 

  5. King CR, Kraus MH, Aaronsen SA (1985) Amplification of a novel v-erb-related gene in a human mammary carcinoma. Science. 229:974–6

    Article  CAS  PubMed  Google Scholar 

  6. Depowski P, Mulford D, Minot P et al (2002) Comparative analysis of HER-2/neu protein overexpression in breast cancer using paraffin-embedded tissue and cytologic specimens. Mod Pathol. 15:70A

    Google Scholar 

  7. Joensuu H, Isola J, Lundin M et al (2003) Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0Mo breast cancer: a nationwide population-based study. Clin Cancer Res. 9:923–30

    CAS  PubMed  Google Scholar 

  8. Press MF, Bernstein PA, Thomas LF et al (1997) HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 15:2894–904

    CAS  PubMed  Google Scholar 

  9. Muss HB, Thor AD, Berry DA et al (1994) c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 330:1260–6

    Article  CAS  PubMed  Google Scholar 

  10. Paik S, Bryant J, Park C et al (1998) erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 90:1361–70

    Article  CAS  PubMed  Google Scholar 

  11. Thor AD, Berry DA, Budman DR et al (1998) erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 90:1346–60

    Article  CAS  PubMed  Google Scholar 

  12. Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 21:2787–99

    Article  CAS  PubMed  Google Scholar 

  13. Klapper L, Waterman H, Sela M et al (2000) Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res. 60:3384–88

    CAS  PubMed  Google Scholar 

  14. Molina MA, Codony-Servat J, Albanell J et al (2001) Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res. 61:4744–9

    CAS  PubMed  Google Scholar 

  15. Clynes RA, Towers TL, Presta LG et al (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 6:443–6

    Article  CAS  PubMed  Google Scholar 

  16. Izumi Y, Xu L, di Tomaso E et al (2002) Tumour biology: herceptin acts as an anti-angiogenesis cocktail. Nature. 416:279–80

    Article  CAS  PubMed  Google Scholar 

  17. Cobleigh MA, Vogel CL, Tripathy D et al (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 17(9):2639–48

    CAS  PubMed  Google Scholar 

  18. Baselga J, Carbonell X, Castaneda-Soto NJ et al (2005) Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol. 23(10):2162–71

    Article  CAS  PubMed  Google Scholar 

  19. Vogel CL, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 20(3):719–26

    Article  CAS  PubMed  Google Scholar 

  20. Pegram MD, Konecny GE, O’Callaghan C et al (2004) Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst. 96(10):739–49

    Article  CAS  PubMed  Google Scholar 

  21. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344(11):783–92

    Article  CAS  PubMed  Google Scholar 

  22. Marty M, Cognetti F, Maraninchi D et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 23(19):4265–74

    Article  CAS  PubMed  Google Scholar 

  23. Seidman AD, Fornier MN, Esteva FJ et al (2001) Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 19(10):2587–95

    CAS  PubMed  Google Scholar 

  24. Hamberg P, Bontenbal M, Vernhout RM et al Combined trastuzumab/docetaxel versus sequential trastuzumab followed by docetaxel at progression as first-line chemotherapy for HER2-positive metastatic breast cancer: preliminary results (multicenter BOOG-study; 2002-02). San Antonio Breast Cancer Symposium, San Antonio, 13th–16th Dec 2007; abstr 1077

    Google Scholar 

  25. Pegram MD, Finn RS, Arzoo K et al (1997) The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene. 15(5):537–47

    Article  CAS  PubMed  Google Scholar 

  26. Robert N, Leyland-Jones B, Asmar L et al (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 24(18):2786–92

    Article  CAS  PubMed  Google Scholar 

  27. Pegram M, Forbes JF, Pienkowski T, et al BCIRG 007: first overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first-line therapy in HER2 amplified metastatic breast cancer. J Clin Oncol. 2007;25:34s; abstr

    Google Scholar 

  28. Burstein HJ, Harris LN, Marcom PK et al (2003) Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 21(15):2889–95

    Article  CAS  PubMed  Google Scholar 

  29. Jahanzeb M, Mor JE, Yunus F et al (2002) Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+)metastatic breast cancer. Oncologist. 7(5):410–7

    Article  CAS  PubMed  Google Scholar 

  30. Burstein HJ, Kuter I, Campos SM et al (2001) Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 19(10):2722–30

    CAS  PubMed  Google Scholar 

  31. Chan A, Martin M, Untch M et al (2006) Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. Br J Cancer. 95(7):788–93

    Article  CAS  PubMed  Google Scholar 

  32. Fujimoto-Ouchi K, Sekiguchi F, Tanaka Y (2002) Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5′-dFUrd in human breast cancer models. Cancer Chemother Pharmacol. 49:211–6

    Article  CAS  PubMed  Google Scholar 

  33. Schaller G, Fuchs I, Gonsch T et al (2007) Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol. 25(22):3246–50

    Article  CAS  PubMed  Google Scholar 

  34. Xu L, Song S, Zhu J et al (2004) Results of a phase II trial of Herceptin® plus Xeloda® in patients with previously untreated HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 88(Suppl 1):S128

    Google Scholar 

  35. O’Shaughnessy JA, Vukelja S, Marsland T et al (2004) Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer. 5(2):142–7

    Article  PubMed  Google Scholar 

  36. Wardley A, Antón-Torres A, Pivot X, et al Trastuzumab plus docetaxel with or without capecitabine in patients with HER2-positive advanced/metastatic breast cancer: first efficacy results from the phase II MO16419 (CHAT) study. Breast Cancer Res Treat. 2006;100: abstr 2063

    Google Scholar 

  37. Perez EA, Suman VJ, Rowland KM et al (2005) Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 6(5):425–32

    Article  CAS  PubMed  Google Scholar 

  38. Polyzos A, Mavroudis D, Boukovinas J, et al A multicenter phase II study of docetaxel, gemcitabine and trastuzumab administration as first-line treatment in patients with advanced breast cancer (ABC) overexpressing HER-2. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004;22(Suppl 14S):728

    Google Scholar 

  39. Fountzilas G, Christodoulou C, Tsavdaridis D et al (2004) Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). Cancer Invest. 22(5):655–62

    Article  CAS  PubMed  Google Scholar 

  40. Venturini M, Bighin C, Monfardini S et al (2006) Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 95(1):45–53

    Article  CAS  PubMed  Google Scholar 

  41. Yardley DA, Greco FA, Porter LL, et al First-line treatment with weekly docetaxel, vinorelbine, and trastuzumab in HER2-overexpressing metastatic breast cancer (HER2+ MBC): A Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004;22(Suppl 14S):643

    Google Scholar 

  42. Arpino G, Green SJ, Allred DC et al (2004) HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group Study. Clin Cancer Res. 10(17):5670–6

    Article  CAS  PubMed  Google Scholar 

  43. Fornier MN, Seidman AD, Panageas KS et al (2002) Correlation of ER/PR [immunohistochemistry (IHC)] status to HER2 status by IHC and gene amplification (GA) [fluorescent in-situ hybridization (FISH)], and response rate (RR) for weekly (W) trastuzumab (H) and paclitaxel (T) in metastatic breast cancer (MBC) patients (pts). Proc Am Soc Clin Oncol. 21:56a

    Google Scholar 

  44. Pinto AE, Andre S, Pereira T et al (2001) C-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis. Ann Oncol. 12:525–33

    Article  CAS  PubMed  Google Scholar 

  45. Lipton A, Ali SM, Leitzel K et al (2002) Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol. 20:1467–72

    Article  CAS  PubMed  Google Scholar 

  46. Benz CC, Scott GK, Sarup JC et al (1993) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 24:85–95

    Article  CAS  Google Scholar 

  47. Mackey JR, Kaufman B, Clemens M, et al Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2006;100: abstr 3

    Google Scholar 

  48. Ellis MJ, Coop A, Singh B et al (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 19:3808–16

    CAS  PubMed  Google Scholar 

  49. Marcom PK, Isaacs C, Harris L et al (2007) The combination of letrozole and trastuzumab as first-or second-line biological therapy produces durable responses in a subset of HER2-positive and ER-positive advanced breast cancers. Breast Cancer Res Treat. 102(1):43–9

    Article  CAS  PubMed  Google Scholar 

  50. Tripathy D, Slamon DJ, Cobleigh M (2004) Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 22(6):1063–70

    Article  CAS  PubMed  Google Scholar 

  51. Fountzilas G, Razis E, Tsavdaridis D et al (2003) Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group. Clin Breast Cancer. 4(2):120–5

    Article  CAS  PubMed  Google Scholar 

  52. Gelmon KA, Mackey J, Verma S. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer. 2004;5:52–8; discussion 59–62

    Article  CAS  PubMed  Google Scholar 

  53. Von Minckwitz G, Vogel P, Schmidt M, et al Trastuzumab treatment beyond progression in patients with HER2-positive metastatic breast cancer — the TBP study (GBG 26/BIG 3-05). San Antonio Breast Cancer Symposium, San Antonio, 13th–16th Dec 2007; abstr 4056

    Google Scholar 

  54. Pusztai L, Esteva FJ (2006) Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER2-positive metastatic breast cancer. Cancer Invest. 24(2):187–91

    Article  CAS  PubMed  Google Scholar 

  55. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy HER2-positive breast cancer. N Engl J Med. 353:1659–72

    Article  CAS  PubMed  Google Scholar 

  56. Smith I, Procter M, Gelber RD et al (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet. 369:29–36

    Article  CAS  PubMed  Google Scholar 

  57. Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 353:1673–84

    Article  CAS  PubMed  Google Scholar 

  58. Perez EA, Romond H, Suman VJ, et al Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings. 2007;25(18s):LBA512

    Google Scholar 

  59. Slamon D, Eiermann W, Robert N, et al Phase III randomized trial comparing doxorubicin and cyclophosphamide, followed by docetaxel (ACT) with doxorubicin and cyclophosphamide, followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2-positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat. 2005;94(Suppl 1):S5; abstr 1

    Google Scholar 

  60. Slamon D, Eiermann W, Robert N, et al BCIRG 006: 2nd interim analysis phase III randomized trial phase III comparing doxorubicin and cyclophosphamide, followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide, followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2-positive early breast cancer patients: Breast Cancer Res Treat. 2006;100, General Session 2; abstr S2

    Google Scholar 

  61. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 354:809–20

    Article  CAS  PubMed  Google Scholar 

  62. Spielmann M, Roche H, Humblet Y, et al 3-year follow-up of trastuzumab following adjuvant chemotherapy in nodepositive HER2-positive breast cancer patients: results of the PACS-04 trial. San Antonio Breast Cancer Symposium, San Antonio, 13th–16th Dec; abstr 72

    Google Scholar 

  63. Tan-Chiu E, Yothers G, Romond E et al (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 23(31):7811–9

    Article  CAS  PubMed  Google Scholar 

  64. Suter TM, Procter M, van Veldhuisen DJ et al (2007) Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 25:1–8

    Article  CAS  Google Scholar 

  65. Balsega J, Norton L, Albanell J et al (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58:2825–31

    Google Scholar 

  66. Pegram M, Hsu S, Lewis G et al (1999) Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 18:2241–51

    Article  CAS  PubMed  Google Scholar 

  67. Rastogi P, Jeong J, Geyer CE, et al Five-year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)→paclitaxel (T) vs AC→T with trastuzumab (H). J Clin Oncol, 2007 ASCO Annual Meeting Proceedings. 2007;25(18s): LBA512

    Google Scholar 

  68. Pietras RJ, Joseph CP, Gallardo D et al (1999) Monoclonal antibody to HER-2/neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. 59:1347–55

    CAS  PubMed  Google Scholar 

  69. Halyard MY, Pisansky TM, Solin LJ, et al Adjuvant radiotherapy and trastuzumab in stage I–IIA breast cancer: toxicity data from North Central Cancer Treatment Group Phase III trial N9831. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings. 2006;24(18s):LBA523

    Google Scholar 

  70. Leyland-Jones B, Gelmon K, Ayoub JP et al (2003) Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol. 21:3965–71

    Article  CAS  PubMed  Google Scholar 

  71. Perez EA, Suman VJ, Davidson N, et al NCCTG-N9831. May 2005 Update. Slide presentation at the 41st American Society of Clinical Oncology Annual Meeting, Orlando, Florida, May 13–17, 2005. Available at http://www.asco.org/ac/1,10003,_12-002511-00_18-0034-00_19-005815-00_21-001,00.asp

    Google Scholar 

  72. Esteva FJ, Valero V, Booser D et al (2002) Phase II study of weekly docetaxel and trastuzumab for patients with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 20(7):1800–8

    Article  CAS  PubMed  Google Scholar 

  73. Albanell J, Baselga J (2001) Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect. J Natl. Cancer Inst. 93:1830–2

    Article  CAS  PubMed  Google Scholar 

  74. Nagy P, Friedlander E, Tanner M et al (2005) Decreased accessibility and lack of activation or ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res. 65:473–82

    CAS  PubMed  Google Scholar 

  75. Nagata Y, Lan KH, Zhou X et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 6:117–27

    Article  CAS  PubMed  Google Scholar 

  76. Nahta R, Takahashi T, Ueno NT et al (2004) p27(kip1) downregulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res. 64(11):3981–6

    Article  CAS  PubMed  Google Scholar 

  77. Lu YH, Zi XL, Zhao DJ et al (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Nat Cancer Inst. 93:1852–7

    Article  CAS  PubMed  Google Scholar 

  78. Nahta R, Yuan LX, Zhang B et al (2005) Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 65(23):11118–28

    Article  CAS  PubMed  Google Scholar 

  79. Normanno N, De LA CM et al (2002) Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol. 13(1):65–72

    Article  CAS  PubMed  Google Scholar 

  80. Arteaga CL, O’Neil A, Moulder SL, et al ECOG1100: a phase I–II study of combined blockade of the erbB receptor network with trastuzumab and gefitinib “Iressa” in patients with Her2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2004;88:abstr 25

    Google Scholar 

  81. Xia W, Liu LH, Ho P et al (2004) Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene. 23:646–53

    Article  CAS  PubMed  Google Scholar 

  82. Howard A, Burris HA III (2004) Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor Lapatinib. Oncologist. 9(Suppl 3):10–5

    Google Scholar 

  83. Geyer CE, Forster JM, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 355:2733–43

    Article  CAS  PubMed  Google Scholar 

  84. Lin NU, Dieras V, Paul D, et al EGF105084, a phase II study of lapatinib for brain metastases in patients with HER2+ breast cancer following trastuzumab-based systemic therapy and cranial radiotherapy. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. 2007;25(Suppl 18S):1012

    Google Scholar 

  85. Rabindran SK, Discafani CM, Rosfjord EC et al (2004) Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 64:3958

    Article  CAS  PubMed  Google Scholar 

  86. Wong KK, Fracasso PM, Bukowski RM, et al HKI-272: an irreversible pan-erbB receptor tyrosine kinase inhibitor: preliminary phase 1 results in patients with solid tumors. J Clin Oncol. 2006;24(Suppl 18):abstr 3018

    Google Scholar 

  87. Franklin MC, Carey KD, Vajdos FF et al (2004) Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 5:317–28

    Article  CAS  PubMed  Google Scholar 

  88. Jackson JG, St Clair P, Sliwkowski MX et al (2004) Blockade of epidermal growth factor-or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res. 64:2601–9

    Article  CAS  PubMed  Google Scholar 

  89. Cortes J, Baselga J, Kellokumpu-Lehtinen J, et al Open label, randomized, phase II study of pertuzumab in patients with metastatic breast cancer with low expression of HER2. J Clin Oncol 2005 ASCO Annual Meeting Proceedings. 2005;23(16S), Part I of II (Suppl):3068

    Google Scholar 

  90. Baselga J, Cameron D, Miles D, et al Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC), which has progressed during treatment with T. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007;25(Suppl 18S):1004

    Google Scholar 

  91. Petit AM, Rak J, Hung MC et al (1997) Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 151:1523–30

    CAS  PubMed  Google Scholar 

  92. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:27–31

    Article  CAS  PubMed  Google Scholar 

  93. Kim KJ, Li B, Winer J et al (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841–4

    Article  CAS  PubMed  Google Scholar 

  94. Pegram M, Yeon C, Ku NC. Phase 1 combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 prot-oncogene and vascular endothelial growth factor. Breast Cancer Res Treat. 2004;88(Suppl):S124; abstr 3039

    Google Scholar 

  95. Pegram M, Chan D, Dichmann RA, et al Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab and bevacizumab as first-line treatment of HER2-amplified breast cancer. Breast Cancer Res Treat. 2006;100(Suppl 1): S28; abstr 301

    Google Scholar 

  96. Study NCT00520975: First-line chemotherapy and trastuzumab with or without bevacizumab in treating patients with metastatic breast cancer that overexpresses HER-2/Neu. Available at www.clinicaltrials.gov

    Google Scholar 

  97. Dejonge M, Savage S, Verweij J, et al A phase I, open-label study of the safety and pharmacokinetics of pazopanib and lapatinib administered concurrently. J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I. 2006;24(Suppl 18S):3088

    Google Scholar 

  98. Study NCT00347919: A Phase II, Open-Label, Randomized, Multicenter Trial of GW786034 (Pazopanib) in Combination With Lapatinib (GW572016) Compared to Lapatinib Alone as First-line Therapy in Subjects With Advanced or Metastatic Breast Cancer With ErbB2 Fluorescence In Situ Hybridization (FISH) Positive Tumors. Available at www. clinicaltrials.gov

    Google Scholar 

  99. Grem JL, Morrison G, Guo XD et al (2005) Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol. 23:1885–93

    Article  CAS  PubMed  Google Scholar 

  100. Modi S, Stopeck A, Gordon MS, et al Phase I trial of KOS-953, a heat shock protein 90 inhibitor, and trastuzumab. J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I. 2006;24(Suppl 18S):501

    Google Scholar 

  101. Modi S, Stopeck A, Kinden H, et al Tanespimycin (an Hsp90 inhibitor) and trastuzumab is an active combination in patients with HER2-positive trastuzumab-refractory metastatic breast cancer: phase 2 trial. San Antonio Breast Cancer Symposium, San Antonio: 13th–16th Dec 2007: abstr 6066

    Google Scholar 

  102. Modi S, Beeram M, Krop IE, et al A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2-antibody drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC). ASCO 2007 Breast Cancer Symposium; abstr 168

    Google Scholar 

  103. NCT00509769. A phase II, single-arm, open-label study of trastuzumab-MCC-DM1 administered intravenously to patients with HER2-positive metastatic breast cancer who have progressed while receiving HER2-directed therapy, available at www.clinicaltrials.gov

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut Jules Bordet, Université Libre de Bruxelles (U.L.B), 121 Blvd de Waterloo, 1000, Brussels, Belgium

    Phuong Dinh & Gianluca Tomasello

  2. Department of Medical Oncology, Jules Bordet Institute, 121 Blvd de Waterloo, 1000, Brussels, Belgium

    Martine J. Piccart

Authors
  1. Phuong Dinh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gianluca Tomasello
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martine J. Piccart
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Phuong Dinh .

Editor information

Editors and Affiliations

  1. Breast Care Center National Naval Medical Center, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd., Bethesda, MD, 20814, USA

    Ismail Jatoi (Head) (Head)

  2. Women’s Hospital, University of Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany

    Manfred Kaufmann (Breast Unit Director) (Breast Unit Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Dinh, P., Tomasello, G., Piccart, M.J. (2010). HER2-Targeted Therapy. In: Jatoi, I., Kaufmann, M. (eds) Management of Breast Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-69743-5_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-69743-5_20

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-69742-8

  • Online ISBN: 978-3-540-69743-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation